Beta Bionics
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · California, United States · 201-500 Employees
View Company Info for Free
Overview
Headquarters
11 Hughes, Irvine, California, 92618, Un...Phone Number
(855) 745-3800Website
www.betabionics.comRevenue
$110.2 MillionStock Symbol
BBNXIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Beta Bionics
Beta Bionics® is a clinical stage medical technology company focused on the design, development, and commercialization of its iLet® Bionic Pancreas System. The iLet Bionic Pancreas is designed to use adaptive, self-learning, control algorithms, together with continuous glucose monitoring and pump technology, to autonomously compute and administer doses of insulin and/or glucagon and mimic the body's natural ability to maintain tight glycemic control. Beta Bionics is a for-profit, public benefit corporation and Certified B Corporation. Since its founding in 2015, its mission has been to help improve health outcomes and the quality of life of children and adults living with diabetes and other conditions of glycemic dysregulation. Beta Bionics operates in Massachusetts and California.Explore more
Beta Bionics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Beta Bionics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Beta Bionics, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Beta Bionics has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Beta Bionics
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Beta Bionics recently announced quarterly report
Product Launch: Get notified when Beta Bionics launches new products
Click to see if Beta Bionics had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Beta Bionics has new funding data
Check out if Beta Bionics is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Reach out to Masked Content who joined Beta Bionics as Masked Content
Find 3 more new buyers
Compare Similar Companies to Beta Bionics
Compare insights from companies similar to Beta Bionics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Beta Bionics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Beta Bionics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Beta Bionics.
Beta Bionics financials insights
Gather financial insights about Beta Bionics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2016
Angel/Seed
$1M
2017
Private Equity
$2.5M
2019
Series B
$63M
2022
Series C
$57M
2023
Series D
$100M
2024
Series E
$60M
2025
Stock Offering
$212.1M
Beta Bionics Tech Stack
A closer look at the technologies used by Beta Bionics
See more technologies
Most Recent Scoops
Open Position
Earnings
Earnings, Finance
Person-Based
Product Launch
Open Position
Open Position
Beta Bionics News & Media
Beta Bionics Announces Second Quarter 2026 Financial Results and Updates Full Year 2026 Guidance
IRVINE, Calif., July 29, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial results for the quarter ended June 30, 2026 and updated its full year guidance for the year ending December 31, 2026.Beta Bionics to Announce Second Quarter 2026 Financial Results on July 29, 2026
IRVINE, Calif., July 01, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to release its second quarter 2026 financial results after the financial markets close on Wednesday, July 29, 2026. Management will host a conference call and concurrent webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to review the company’s second quarterBeta Bionics (BBNX) Securities Investigation: Johnson Fistel Reviews Investor Losses Following Slower New Patient Start Growth
SAN DIEGO, June 12, 2026 /PRNewswire/ -- Johnson Fistel, PLLP is investigating potential securities law violations on behalf of investors of Beta Bionics, Inc. (NASDAQ: BBNX). The investigation concerns whether Beta Bionics or certain of its executive officers made false or misleading...Robbins LLP Reminds BBNX Stockholders of its Investigation into Beta Bionics, Inc.; Contact the Firm for Information
Robbins LLP Reminds BBNX Stockholders of its Investigation into Beta Bionics, Inc.; Contact the Firm for Information
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Beta Bionics
Sign Up For FreeTo access detailed company insights
Beta Bionics® is a clinical stage medical technology company focused on the design, development, and commercialization of its iLet® Bionic Pancreas System. The iLet Bionic Pancreas is designed to use adaptive, self-learning, control algorithms, together with continuous glucose monitoring and pump technology, to autonomously compute and administer d... Read More
